Google Alert - "Myeloproliferative neoplasms" OR "polycythemia vera" OR myelofibrosis OR "essential thrombocythemia" · Scour

Prelude Therapeutics Reports First Quarter 2026 Financial

Essential Thrombocythemia Therapeutics Market Size was found

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and ...

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and ...

AN2 Therapeutics Q1 2026 loss $10M, cash $85.3M

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and ...

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

Incyte stock (US45337C1027): Biotech name with S&P 500 exposure and pipeline growth story

Five Under 5: Top Oncology Videos for the Week of 5/3

A Phase 1 Randomized, Double-Blind, Placebo-Controlled Single and Multiple ...

Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding ...

Oncologist on Hantavirus Cruise; Bile Duct Cancer Drug OK'd; Untreated Lung Cancers

Real-world patient characteristics and clinical outcomes in patients with myelofibrosis in Japan

Ono's Phase 3 Sapablursen Trial Targets Polycythemia Vera Upside for OPHLF Investors

Study Links Transfusion Independence With Quality of Life in MF

Weekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs ...

LLM Tool Significantly Reduces Participant Screening Burdens, Improves Enrollment for ...

Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Blastic Crisis in a ...

Impact of thrombosis on disease progression, cancer and mortality in patients with essential ...

FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications

Log in to enable infinite scrolling